Intellia Therapeutics Inc 's Cash & cash equivalent grew by 16.43 % in the Q2 2026 sequentially, faster than Current Liabilities, this led to improvement in Intellia Therapeutics Inc 's Quick Ratio to 5.51, Quick Ratio remained below Intellia Therapeutics Inc average.

Within In Vitro & In Vivo Diagnostic Substances industry only one company has achieved higher Quick Ratio in second quarter 2026. While Quick Ratio total ranking has improved so far during the Q2 2026 to 832, from total ranking in the first quarter 2026 at 1068.

Explain Quick Ratio?
How much Cash & cash equivalents NTLA�s has?
What are NTLA�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

NTLA Quick Ratio	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2
Y / Y Current Liabilities Change	-16.87 %	-32.11 %	-6.29 %	-11.31 %	-9.13 %
Y / Y Cash & cash equivalent Change	-4.76 %	-25.36 %	-25.21 %	-22.35 %	-33.49 %
Quick Ratio MRQ	5.51	4.92	4.33	5.45	4.81
NTLA's Total Ranking	# 832	# 1068	# 841	# 917	# 986
Seq. Current Liabilities Change	3.86 %	-26.41 %	10.84 %	-1.86 %	-15.18 %
Seq. Cash & cash equivalent Change	16.43 %	-16.43 %	-11.97 %	11.18 %	-8.75 %

Quick Ratio second quarter 2026 Company Ranking
Within:	No.
In Vitro & In Vivo Diagnostic Substances Industry	# 2
Healthcare Sector	# 284
Overall Market	# 759

Quick Ratio Statistics
High	Average	Low
13.91	8.01	4.33
(Jun 30 2016)		(Dec 31 2025)

Financial Statements
Intellia Therapeutics Inc 's Current Liabilities	$ 79 Millions	Visit NTLA's Balance sheet
Intellia Therapeutics Inc 's Cash & cash equivalent	$ 438 Millions	Visit NTLA's Balance sheet
Source of NTLA's Sales		Visit NTLA's Sales by Geography

Cumulative Intellia Therapeutics Inc 's Quick Ratio

NTLA's Quick Ratio for the trailling 12 Months

NTLA Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	-16.76 %	-14.89 %	-3.3 %	-2.65 %	3.53 %
Y / Y Cash & cash equivalent TTM Growth	-20.17 %	-26.8 %	-29.82 %	-32 %	-31.59 %
Quick Ratio TTM	5.02	4.86	4.74	5.03	5.24
Total Ranking TTM	# 846	# 1056	# 747	# 863	# 936
Seq. Current Liabilities TTM Growth	-4.36 %	-8.91 %	-1.69 %	-2.82 %	-2.21 %
Seq. Cash & cash equivalent TTM Growth	-1.22 %	-6.64 %	-7.3 %	-6.62 %	-9.43 %

Quick ratio ranking by company, industry and sector >> Back to NTLA Financial Strength Comparisons >> Go to Compare NTLA Quick Ratio to its Competitors

On the trailing twelve months basis Current Liabilities decreased faster than Intellia Therapeutics Inc 's average Cash & cash equivalent, this led to increase in in Intellia Therapeutics Inc 's Quick Ratio to 5.02, above NTLA average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within In Vitro & In Vivo Diagnostic Substances industry 14 other companies have achieved higher Quick Ratio than Intellia Therapeutics Inc . While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending first quarter 2026 at 3677.

Explain Quick Ratio?
How much Cash & cash equivalents NTLA�s has?
What are NTLA�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the In Vitro & In Vivo Diagnostic Substances Industry	# 15
Healthcare Sector	# 885
Within the Market	# 832

trailing twelve months Quick Ratio Statistics
High	Average	Low
11.73	4.05	1.08
(Sep 30 2018)		(Sep 30 2022)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within In Vitro & In Vivo Diagnostic Substances Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
Celldex Therapeutics inc	11.70	$ 717.587 Millions	$ 61.325 Millions
Intellia Therapeutics Inc	5.51	$ 437.759 Millions	$ 79.392 Millions
Qc Technologies Inc	3.00	$ 10.987 Millions	$ 3.669 Millions
Alpha Teknova Inc	2.54	$ 17.436 Millions	$ 6.872 Millions
Lantheus Holdings Inc	1.77	$ 593.298 Millions	$ 335.677 Millions
Insight Molecular Diagnostics Inc	1.73	$ 17.756 Millions	$ 10.286 Millions
Achieve Life Sciences Inc	1.65	$ 326.645 Millions	$ 197.657 Millions
Immucell Corporation	1.51	$ 8.860 Millions	$ 5.863 Millions

Date modified: 2026-09-26T07:28:20+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.